comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 12:17:27 Page View：3123

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Summit: Biotech founders on deal
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Why Eli Lilly’s earnings didn’t quite live up to the hype

KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

First Opinion Podcast: Long Covid needs a new approach

Sincetheearlydaysofthepandemic,longCovidhashauntedus:Evenamildacuteinfectionmightleaveyouwithlife-al

comprehensive

focus

explore

First Opinion Podcast: Long Covid needs a new approach